Assessment of the Long-term Safety and Efficacy of Erenumab During Open-label Treatment in Patients With Chronic Migraine

Stewart J. Tepper,1 Messoud Ashina,2 Uwe Reuter,3 Jan L. Brandes,4 David Doležil,5 Stephen Silberstein,6 Paul Winner,7 Feng Zhang,8 Sunfa Cheng,9 Daniel D. Mikol9

Brief Overview

• Erenumab demonstrated sustained efficacy at one year
• Erenumab was safe and well tolerated in patients with chronic migraines, with no new safety events and no reported dose-dependent adverse events
• Patients who completed the 52-week open-label treatment phase showed a numerically greater benefit with erenumab 140 mg compared to 70 mg at weeks 40 and 52 for
- Change in monthly migraine days from the double-blind treatment phase baseline
- Rate of reduction in monthly migraine days
- Change in monthly use days for acute migraine-specific medication (AMSM) from the double-blind treatment phase (in AMSM users at baseline)
Learn more about the clinical trial background Arrow

1Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 2Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark; 3Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 4Nashville Neuroscience Group and Vanderbilt University Department of Neurology, Nashville, TN, USA; 5Dado Medical sro, Prague Headache Center, Prague, Czech Republic; 6Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 7Premiere Research Institute, Nova Southeastern University, West Palm Beach, FL, USA; 8Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA; 9Global Development, Amgen Inc., Thousand Oaks, CA, USA.